KN046

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

KN046 in Patients With Advanced Non-small Cell Lung Cancer

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors